Clinical Trials Browser

Phase 2 × Neoplasms, Plasma Cell × Fibroblast Growth Factor 7 × Clear all

NCT01237951 2020-05-05

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Phase 2 Completed

75 enrolled 11 charts

Plasma cell

Neoplasms, Plasma Cell

NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Phase 2 Withdrawn

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00004132 2013-06-26

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

Phase 2 Completed

LymphoidOther hematologic neoplasmPlasma cellSarcoma

Blast Crisis, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Radiation Injuries, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating, Drug-Related Side Effects and Adverse Reactions